Glenmede Investment Management, LP Anavex Life Sciences Corp. Transaction History
Glenmede Investment Management, LP
- $19.8 Trillion
- Q2 2025
A detailed history of Glenmede Investment Management, LP transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Glenmede Investment Management, LP holds 288 shares of AVXL stock, worth $2,594. This represents 0.0% of its overall portfolio holdings.
Number of Shares
288Holding current value
$2,594% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AVXL
# of Institutions
196Shares Held
32MCall Options Held
1.16MPut Options Held
804K-
Black Rock Inc. New York, NY6.39MShares$57.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.11MShares$46 Million0.0% of portfolio
-
State Street Corp Boston, MA2.95MShares$26.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.02MShares$18.2 Million0.0% of portfolio
-
Nwam LLC Mercer Island, WA1.02MShares$9.23 Million0.83% of portfolio
About ANAVEX LIFE SCIENCES CORP.
- Ticker AVXL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,942,800
- Market Cap $702M
- Description
- Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...